What Researchers Did
Researchers reviewed the patterns of use, clinical outcomes, and dose-volume histogram parameters of high-dose-rate interstitial brachytherapy (HDR-ISBT) as a boost in five patients with Stage II-III Bartholin's gland carcinoma.
What They Found
All 5 patients received HDR-ISBT as a boost (median dose, 30Gy) after external beam radiotherapy (median dose, 45Gy). A complete response was observed in all patients, with no local recurrence and all remaining alive and free of disease after a median follow-up of 78 months. Severe vaginal toxicities, including necrosis, were noted but resolved with hyperbaric oxygen therapy.
What This Means for Canadian Patients
This study suggests that high-dose-rate interstitial brachytherapy could be an effective treatment option for Canadian patients with Bartholin's gland carcinoma, particularly for positive surgical margins, residual tumor, or locally advanced cases. It offers excellent long-term local control, though potential severe vaginal toxicities should be managed.
Canadian Relevance
The study's authors are Canadian, indicating direct relevance to Canadian medical practice and research in oncology.
Study Limitations
A significant limitation of this study is the very small sample size of only five patients, which limits the generalizability of the findings.